Background Globally, chronic hepatitis B (CHB) is a major public health concern. Timely and
effective management can prevent disease progression to cirrhosis and reduce the risk of …

Hepatitis B virus (HBV) is responsible for more than 50% of hepatocellular carcinoma (HCC)
in HBV hyperendemic areas, such as the Asia-Pacific region. Several hepatitis B viral factors …

Background & Aims Many patients with chronic hepatitis B (CHB) may not conform to any of
the defined phases and hence are classified as indeterminate. We aimed to characterize the …

BACKGROUND It is unclear whether the level of serum hepatitis B virus (HBV) DNA at
baseline affects the on-treatment risk of hepatocellular carcinoma (HCC) in hepatitis B e …

Liver biopsies are recommended to exclude significant liver inflammation in patients with
chronic hepatitis B (CHB) with elevated HBV DNA but without other indications for antiviral …

Background Antiviral treatment in patients with chronic hepatitis B (CHB) may decrease the
risk of hepatocellular carcinoma (HCC) and death. However, only 2.2% of CHB patients …

Background Population‐based data are lacking regarding whether fatty liver is a risk factor
for hepatocellular carcinoma (HCC) and mortality in patients with chronic viral hepatitis. Aim …

Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC)
worldwide. Antiviral treatment reduces the risk of HCC and mortality; nonetheless, globally in …

Metabolic dysfunction‐associated fatty liver disease (MAFLD) can coexist with chronic viral
hepatitis. MAFLD is a heterogeneous disease because the diagnostic criteria include …

Objective The cost-effectiveness of antiviral treatment in adult immune-tolerant (IT) phase
chronic hepatitis B (CHB) patients is uncertain. Design We designed a Markov model to …